September 04, 2014
Article
Until apremilast was approved earlier this year, patients with psoriatic arthritis had to rely primarily on injectable therapies, which contributed to less than optimal treatment adherence in many patients.
August 25, 2014
Patients treated with certolizumab pegol for 24 weeks showed rapid improvement in the signs and symptoms of psoriatic arthritis.
August 21, 2014
When it was approved by the FDA in March 2014, apremilast became the first oral medication approved for the treatment of psoriatic arthritis (PsA). Data from clinical trials showed it to be an effective option for patients, with a safer side effect profile than currently used PsA treatments.
July 09, 2014
Study results show that treatment with etanercept is effective and well tolerated in adolescent patients with psoriatic arthritis and other rheumatic conditions.
Dupilumab Continues to Show Benefit in Treating EoE
The Ketamine & Esketamine Care Teams, and Necessary Monitoring
FDA Approves Tapinarof Cream, 1% for Adults with Plaque Psoriasis